Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

172222

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to his announcement on 20 November 2014 of an Innovative Medicines and MedTech Review, launched on 20 November 2014, what the formal terms of reference are for the review and what the deadline is for the review to report.
tabling member constituency	Hartlepool
tabling member printed	Mr Iain Wright
uin	219836
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>I refer the hon. Member to the Written Ministerial Statement that I made on 20 November 2014, Official Report, column 14WS. The review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology will consider how to speed up access for National Health Service patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The Government is working to establish the formal terms of reference for the review. These will be published in due course. The exact structure of the review is currently being considered and, as appropriate, procurements will be through standard departmental procurement processes.</p><p> </p><p> </p><p> </p><p>The review will set out both short and long-term options for action by Government and relevant bodies — including the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency and NHS England. Officials are already working with these bodies and will continue to do so as the review progresses.</p><p> </p><p> </p><p> </p><p>The review will take into account a wide range of evidence to draw up its recommendations. We anticipate an initial report before the autumn.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219834 219835 219837 question first answered 13/01/2015 11:15:26 answering member 4020 label Biography information for George Freeman
tabling member	1478 label Biography information for Mr Iain Wright

172223

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to his announcement on 20 November 2014 of an Innovative Medicines and MedTech Review, if he will ensure that the review will take into consideration the conclusions of NICE following its consideration of responses to the Value-Based Assessment consultation.
tabling member constituency	Hartlepool
tabling member printed	Mr Iain Wright
uin	219837
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>I refer the hon. Member to the Written Ministerial Statement that I made on 20 November 2014, Official Report, column 14WS. The review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology will consider how to speed up access for National Health Service patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The Government is working to establish the formal terms of reference for the review. These will be published in due course. The exact structure of the review is currently being considered and, as appropriate, procurements will be through standard departmental procurement processes.</p><p> </p><p> </p><p> </p><p>The review will set out both short and long-term options for action by Government and relevant bodies — including the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency and NHS England. Officials are already working with these bodies and will continue to do so as the review progresses.</p><p> </p><p> </p><p> </p><p>The review will take into account a wide range of evidence to draw up its recommendations. We anticipate an initial report before the autumn.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219834 219835 219836 question first answered 13/01/2015 11:15:26 answering member 4020 label Biography information for George Freeman
tabling member	1478 label Biography information for Mr Iain Wright

172233

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to his announcement on 20 November 2014 of an Innovative Medicines and MedTech Review, whether the review will take into account the ongoing Innovation, Health and Wealth refresh.
tabling member constituency	Hartlepool
tabling member printed	Mr Iain Wright
uin	219835
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>I refer the hon. Member to the Written Ministerial Statement that I made on 20 November 2014, Official Report, column 14WS. The review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology will consider how to speed up access for National Health Service patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The Government is working to establish the formal terms of reference for the review. These will be published in due course. The exact structure of the review is currently being considered and, as appropriate, procurements will be through standard departmental procurement processes.</p><p> </p><p> </p><p> </p><p>The review will set out both short and long-term options for action by Government and relevant bodies — including the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency and NHS England. Officials are already working with these bodies and will continue to do so as the review progresses.</p><p> </p><p> </p><p> </p><p>The review will take into account a wide range of evidence to draw up its recommendations. We anticipate an initial report before the autumn.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219834 219836 219837 question first answered 13/01/2015 11:15:26 answering member 4020 label Biography information for George Freeman
tabling member	1478 label Biography information for Mr Iain Wright

172234

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to his announcement on 20 November 2014 of an Innovative Medicines and MedTech Review, how the independent organisation that will run the review will be selected; and what the criteria for the selection will be.
tabling member constituency	Hartlepool
tabling member printed	Mr Iain Wright
uin	219834
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>I refer the hon. Member to the Written Ministerial Statement that I made on 20 November 2014, Official Report, column 14WS. The review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology will consider how to speed up access for National Health Service patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The Government is working to establish the formal terms of reference for the review. These will be published in due course. The exact structure of the review is currently being considered and, as appropriate, procurements will be through standard departmental procurement processes.</p><p> </p><p> </p><p> </p><p>The review will set out both short and long-term options for action by Government and relevant bodies — including the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency and NHS England. Officials are already working with these bodies and will continue to do so as the review progresses.</p><p> </p><p> </p><p> </p><p>The review will take into account a wide range of evidence to draw up its recommendations. We anticipate an initial report before the autumn.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219835 219836 219837 question first answered 13/01/2015 11:15:25 answering member 4020 label Biography information for George Freeman
tabling member	1478 label Biography information for Mr Iain Wright

172242

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges and the Asthma UK Centre for Applied Research about appropriate dosages for treatment of asthma.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	219788
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>We have had no such discussions.</p><p> </p><p><strong> </strong></p><p> </p><p>Prescribing decisions are a matter for clinicians based on their patients’ individual clinical needs and taking relevant advice from sources such as the British National Formulary, the National Institute for Health and Care Excellence, specialty association publications and any local prescribing policies.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 13/01/2015 11:18:09 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon